Pathway Bioventures
VC Fund
Chicago, United States
Pathway Bioventures is a seed-stage life sciences fund investing in next-generation therapeutics, medical devices, and diagnostics companies. It invests in extraordinary teams leveraging novel biotechnology to address major unmet medical needs. They focus on finding and advancing technology at the cutting-edge of biology and engineering.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Pathway Bioventures invests in
Stages Pathway Bioventures invests in
Countries Pathway Bioventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel Jacobs
|
|||
Jacob Segil
|
|||
Matt Martin
|
|||
Investment Focus
Industry
- Biotechnology 7 (54%)
- Medical 4 (31%)
- Life Science 3 (23%)
- Therapeutics 3 (23%)
- Health Care 2 (15%)
Stage
- Seed 6 (46%)
- Series A 3 (23%)
- Pre-Seed 1 (8%)
- Funding Round 1 (8%)
- Debt Financing 1 (8%)
Country
- United States 10 (77%)
- United Kingdom 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Daniel Jacobs
Founder & Managing Director
|
Founder & Managing Director | Total investments: 0 | Find email | |
|
Jacob Segil
Venture Advisor
|
Venture Advisor | Total investments: 0 | Find email | |
|
Matt Martin
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cytospire Therapeutics
|
Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | |
|
Nionyx Bio
|
Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases. | $4M / Seed / Sep 29, 2025 | |
Axonis Therapeutics
|
Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M / Series A / Oct 30, 2024 | |
Modifi Bio
|
Modifi Biosciences is a direct DNA modification developing novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drugdevelopment methods. | $4.3M / Seed / Oct 16, 2023 | |
Afference
|
Afference is an electronics manufacturing company that offers wearables that enable the digital dexterity of 3D digital content. | $1.5M / Pre-Seed / Sep 27, 2023 | |
IpiNovyx Bio
|
IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune and inflammatory diseases. It helps create inhibitors to selectively target the immunoproteasome and modulate specific immune cell types for patients to recover from autoimmune and inflammatory diseases and improve their health. | $10M / Seed / Oct 05, 2021 | |
miRecule
|
MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States. | $5.7M / May 28, 2021 | |
|
miRecule
|
MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States. | $5.7M / Seed / May 28, 2021 | |
CytoVale
|
Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States. | $16.4M / Debt Financing / Jan 04, 2021 | |
Dimension Inx
|
Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois. | $3.2M / Seed / Nov 18, 2020 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Pathway Bioventures invest in?
Pathway Bioventures invests primarily in Biotechnology, Medical and Life Science startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pathway Bioventures?
Public channels for Pathway Bioventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pathway Bioventures?
The team at Pathway Bioventures includes Daniel Jacobs (Founder & Managing Director), Jacob Segil (Venture Advisor) and Matt Martin (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
